An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels<em> in vivo</em>
Felix Schiele(Boehringer Ingelheim (Germany)), Herbert Nar(Boehringer Ingelheim (Germany)), Gerd Luippold(Boehringer Ingelheim (Germany)), Norbert Redemann(Boehringer Ingelheim (Germany)), John E. Park
DORA PSI (Paul Scherrer Institute)
January 1, 2014
Cited by 0
Related Papers
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
The Dissociation of Cohesin from Chromosomes in Prophase Is Regulated by Polo-like Kinase
|Molecular Cell|2002|449
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383